Reference : Practical management of Chronic Myeloid Leukemia in Belgium
Scientific journals : Article
Human health sciences : Hematology
http://hdl.handle.net/2268/172675
Practical management of Chronic Myeloid Leukemia in Belgium
English
Benghiat, FS. []
Beguin, Yves mailto [Université de Liège - ULiège > > GIGA-R : Hématologie >]
Dessars, B. []
Devos, T. []
Lewalle, P. []
Mineur, P. []
Straetmans, N. []
Van Eygen, K. []
Verhoef, G. []
Knoops, L. []
2015
Belgian Journal of Hematology
Ariez Medical Publishing
6
1
16-32
Yes
International
Amsterdam
The Netherlands
[en] Chronic Myeloid Leukemia ; Imatinib ; Nilotinib ; Dasatinib ; Bosutinib ; Ponatinib ; response ; therapy ; drug interactions ; adverse events
[en] Imatinib has drastically changed the outcome of patients with chronic myeloid leukemia (CML), with the majority of them showing a normal life span. Recently, the development of second and third generation tyrosine kinase inhibitors (TKIs) and the possibility of treatment discontinuation made the management of these patients more challenging. In this review, practical management guidelines of CML are presented, adapted to the Belgian situation in 2014. In first line chronic phase patients, imatinib, nilotinib and dasatinib can be prescribed. While second generation TKIs give faster and deeper responses, their impact on long-term survival remain to be determined. The choice of the TKI depends on CML risk score, priority for a deep response to allow a treatment-free remission protocol, age, presence of comorbid conditions, side effect profile, drug interactions, compliance concerns and price. Monitoring the response has to be made according the 2013 ELN criteria, and is based on the bone-marrow cytogenetic response during the first months and on the blood molecular response. Molecular follow-up is sufficient in patients with a complete cytogenetic response. For patients who fail frontline therapy, nilotinib, dasatinib, bosutinib and ponatinib are an option depending of the type of intolerance or resistance. T315I patients are only sensitive to ponatinib, which has to be carefully handled due to cardiovascular toxicity. Advanced phase diseases are more difficult to handle, with treatments including allogeneic stem cell transplantation, which is also an option for patients failing at least two TKIs. The possibility of treatment-free remission and pregnancy are also discussed.
http://hdl.handle.net/2268/172675

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
340.pdfPublisher postprint210.08 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.